(Q34750099)

4 August 2017

1 reference

title

Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosis (English)

1 reference

relapsing-remitting multiple sclerosis

4 August 2017

0 references

0 references

author name string

Michel Chofflon

series ordinal

1 reference

4 August 2017

Ali Frederic Ben-Amor

series ordinal

1 reference

4 August 2017

publication date

1 July 2002

1 reference

Clinical Neurology and Neurosurgery

4 August 2017

published in

1 reference

4 August 2017

volume

104

1 reference

4 August 2017

1 reference

4 August 2017

page(s)

244-248

1 reference

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900046-X

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900046-X

7 January 2021

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900046-X

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900046-X

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900046-X

7 January 2021

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900046-X

7 January 2021

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900046-X

7 January 2021

Axonal transection in the lesions of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900046-X

7 January 2021

In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900046-X

7 January 2021

Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900046-X

7 January 2021

Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900046-X

7 January 2021

The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900046-X

7 January 2021

The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900046-X

7 January 2021

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900046-X

7 January 2021

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900046-X

7 January 2021

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900046-X

7 January 2021

Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900046-X

7 January 2021

Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900046-X

7 January 2021

Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900046-X

7 January 2021

Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900046-X

7 January 2021

Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900046-X

7 January 2021

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900046-X

7 January 2021

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900046-X

7 January 2021

Practice advisory on selection of patients with multiple sclerosis for treatment with Betaseron. Report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900046-X

7 January 2021

Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG]

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900046-X

7 January 2021

10.1016/S0303-8467(02)00046-X

Identifiers

DOI

1 reference

4 August 2017

1 reference